

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS FO. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/726,258	11/29/2000	Vanessa Hsei	P1085R4-1AC1	4895	
75	90 09/30/2003				
Knobbe Martens Olson & Bear LLP Ginger R Dreger Sixteenth Floor			EXAMINER		
			ROARK, JESSICA H		
620 Newport Center Drive Newport Beach, CA 92660			ART UNIT	PAPER NUMBER	
			1644	1644	
			DATE MAILED: 09/30/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/726,258	HSEI ET AL.				
,,	Examiner	Art Unit				
	Jessica H. Roark	1644				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence address				
THE REPLY FILED FAILS TO PLACE THIS APPI Therefore, further action by the applicant is required to av final rejection under 37 CFR 1.113 may <u>only</u> be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	a timely filed amendment which	ation. A proper reply to a				
PERIOD FOR RE	<u>:PLY</u> [check either a) or b)]					
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF TH	g date of the final rejection. IE FINAL REJECTION. See MPEP				
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of t (2) as set forth in (b) above, if checked. Any reply received by the Officitimely filed, may reduce any earned patent term adjustment. See 37 C	f extension and the corresponding amo the shortened statutory period for reply be later than three months after the mail	unt of the fee. The appropriate extension originally set in the final Office action; or				
 A Notice of Appeal was filed on <u>23 July 2003</u>. Appe 37 CFR 1.192(a), or any extension thereof (37 CFF 						
2. The proposed amendment(s) will not be entered be	ecause:					
(a) they raise new issues that would require further	er consideration and/or search (s	see NOTE below);				
(b) they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the				
(d) ☐ they present additional claims without cancelinNOTE:	ng a corresponding number of fi	nally rejected claims.				
3. Applicant's reply has overcome the following rejecti	ion(s): See Continuation Sheet.					
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed amendment				
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.						
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly				
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims wo	• • • • • • • • • • • • • • • • • • • •					
The status of the claim(s) is (or will be) as follows:	Du.					
Claim(s) allowed:	JE OFFI Destro	wpG/mpc				
Claim(s) objected to: <u>29</u> .	PRIM	P GAMBEL, PH.D ARY EXAMINER				
Claim(s) rejected: <u>1,25,26,28 and 31-36</u> .	TE	CH CONTIN 1600				
Claim(s) withdrawn from consideration: <u>20</u> .		9/14/03				
8. The proposed drawing correction filed on is a	a) approved or b) disapp					
9. Note the attached Information Disclosure Statemen						
10. Other:	(-)(-				

Continuation of 3. Applicant's reply has overcome the following rejection(s):
a) The previous rejection of claims 1, 25-26, 28-29 and 31-36 under 35 U.S.C. 112, second paragraph;

- b) The Declaration under 37 CFR 1.132 filed 7/23/03 (originally filed in parent application 09/234182) is sufficient to overcome the rejection of claims 1, 25-26, 28-29 and 31-36 based upon either U.S. Pat. No. 6,133,426 (of record) or U.S. Pat. No. 6,025,158 (of record) by establishing that the invention disclosed but not claimed in the 426 and 158 patents was not "by another".
- c) The previous provisional rejection of claims 1, 25-26, 28-29 and 31-36 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 5, 10-13, 15-19, 21, 24-26 and 28-34 of copending Application No. USSN 09/355,014.

It is noted that the terminal disclaimer filed on 7/23/03 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of USSN 09/355,014 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Continuation of 5. does NOT place the application in condition for allowance because:

Applicant's arguments regarding the rejections of record in Paper No. 14 under 35 USC 103(a) appear to be essentially the same as those addressed in Paper No. 14. Applicant continues to argue that there was no motivation to combine the references because the glomerular cutoff was known to be about 70kD and that at best the teachings of the references create an "obvious to try" situation.

The Examiner's position is of record in Paper No. 14.

The proposed amendment to the claims does not alter the rejections of record under 35 USC 103(a); therefore, the following rejections are maintained:

- a) The rejection of claims 1, 25, 31-33 and 36 under 35 U.S.C. § 103(a) as being unpatentable over Zapata et al. (FASEB J. 1995, Abstract #1288, 9:A1479, IDS # 98) in view of Braxton (US Pat. No. 5,766,897, IDS #20);
- b) The rejection of claims 26 and 28 under 35 U.S.C. § 103(a) as being unpatentable over Zapata et al. (FASEB J. 1995, Abstract #1288, 9:A1479, IDS # 98) in view of Braxton (US Pat. No. 5,766,897, IDS #20) as applied to claims 1, 25, 31-33 and 36 above, and further in view of Doerschuk et al (U.S. Patent No. 5,702,946, IDS #18); and
- c) the rejection of claims 34 and 35 under 35 U.S.C. § 103(a) as being unpatentable over Zapata et al. (FASEB J. 1995, Abstract #1288, 9:A1479, IDS # 98) in view of Braxton (US Pat. No. 5,766,897, IDS #20) as applied to claims 1, 25, 31-33 and 36 above, and further in view of Griffiths et al (U.S. Patent No. 5,670,132, IDS #13).